Chronic Kidney Disease

ISN TrialWatch

Trialwatch
home

ISN TrialWatch | Jan – Feb – March 2026

IVIG Modulates Fibrosis and Stabilizes Chronic Active AMR Progression
This phase 2 randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of BI 764198, a selective oral inhibitor of the TRPC6 channel, in adults with biopsy-confirmed primary or TRPC6-related genetic focal segmental glomerulosclerosis (FSGS).
Trial of the month:

ISN TrialWatch | Oct – Nov – Dec 2025

IVIG Modulates Fibrosis and Stabilizes Chronic Active AMR Progression
A randomized controlled trial of intravenous immunoglobulin vs standard of care for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients. Chronic active antibody-mediated rejection (AMR) is the primary cause of kidney allograft loss beyond 5 years and currently has no evidence-based long-term therapy.
Trial of the month:

ISN TrialWatch | Aug – Sept 2025

Spironolactone did not ACHIEVE cardiovascular risk reduction in dialysis
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international,The ACHIEVE trial randomized 2,538 hemodialysis and peritoneal dialysis patients who tolerated a 4-week spironolactone run-in (25 mg daily) to spironolactone versus placebo, with a median follow-up of 1.8 years. Approximately 63% of participants were male, 43% had diabetic kidney disease, and the mean age was 62 years.
Trial of the month:

ISN TrialWatch | June – July 2025

Stronger Together: Finerenone & Empagliflozin Boost Kidney Outcomes in Diabetes
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes The CONFIDENCE trial was a double-blind, randomized study enrolling 800 participants with chronic kidney disease (CKD) (eGFR 30–90 ml/min/1.73 m²), albuminuria (urinary albumin-to-creatinine ratio [UACR] 100– 5000 mg/g), and type 2 diabetes, all of whom were receiving renin–angiotensin system inhibitors. Participants were randomly assigned in a 1:1:1 ratio to...
Trial of the month:

ISN TrialWatch | Apr – May 2025

DAPA-Tolvaptan: First trial of SGLT2 inhibition in ADPKD with background tolvaptan therapy
In this open-label, crossover trial, 27 autosomal dominant polycystic kidney disease (ADPKD) participants on stable high-dose tolvaptan (>60mg/day, >3 months, with eGFR >25 ml/min/1.73 m2) were randomized to receive dapagliflozin 10mg daily or usual care for 6-months, then crossed to the alternate arm for another 6 months, without a washout period.
Trial of the month:

ISN TrialWatch | Feb – Mar 2025

Remote monitoring for automated PD improves cardiovascular outcomes
A device integrated into the automated PD cycler facilitates remote monitoring (RM) of automated peritoneal dialysis (APD), enabling medical staff to track essential PD parameters. This multicentre, clusterrandomized, open-label trial included 403 patients in the RM-APD group and 398 patients in the conventional treatment group.
Trial of the month: